Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

10th Euro-Global Conference on Infectious Diseases

Rome, Italy

Fekadu Abebe

Fekadu Abebe

University of Oslo, Norway

Title: Synergy (not polarization) between Th1 and Th2 responses against Mycobacterium tuberculosis infection: Evidence from an endemic setting

Biography

Biography: Fekadu Abebe

Abstract

At present, tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) kills an estimated 2 million people globally, more people than HIV/AIDS and malaria combined. The only licensed vaccine currently in use, BCG does not control Mtb transmission. Efforts to develop an efficacious vaccine against Mtb infection during the last three decades have achieved moderate success because of lack of knowledge about correlates of protective immunity and the Th1/Th2 paradigm. According to the Th1/Th2 paradigmTh1 cells protect against intracellular pathogens, whereas Th2 cells protect against extracellular pathogen. In the past, it was generally accepted that interferon-gamma (IFN-γ)-producing Th1 cells are protective against Mtb infection, whereas the role antibodies was ignored. Earlier, we have argued that antibodies may play a crucial role against TB (Abebe & Bjune, 2007) and that IFN-γ may not be the right marker for protective immunity against TB (Abebe, 2012). As a part of a major project to identify protective immune markers in Mtb endemic population, we assessed specific antibody and cytokine responses against selected Mtb antigens (LAM, Rv2031, HBHA, the 38-kDa antigen, and ESAT-6/CFP-10) in pulmonary TB patients (PTBP), their household contacts (HHCs) and community controls (CCs) longitudinally. 

Our results show that the levels of IFN-γ (Th1) and IgA (Th2) against HBHA (a promising candidate vaccine) were elevated concurrently in CCs (with no history of clinical TB) compared to PTBP and HHCs (Mtb infected). On the other hand, the level of IFN-γ against ESAT-6/CFP-10 (another candidate vaccine) was elevated in PTBP but was depressed in HHCs and CCs (with no clinical TB). Results of the present study may suggest that there is a synergy between Th1 (IFN-γ) and Th2 (IgA) responses against HBHA of Mtb. These results will be discussed in line with emerging evidence for the protective role of antibodies agains Myb infection and the Th1/Th2 paradigm.